Kate Buccilli

35 Poplar Road
Melbourne, VIC 3052, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.

Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.

Journal: Schizophrenia bulletin open

Published: August 27, 2025

Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program.

Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program.

Journal: Schizophrenia bulletin open

Published: August 27, 2025

Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-Schizophrenia.

Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-Schizophrenia.

Journal: Schizophrenia bulletin

Published: March 26, 2025

Exploring the Relationship Between Inflammatory Biomarkers and Negative Symptoms Subtypes in Individuals at Ultra-High Risk for Psychosis.

Exploring the Relationship Between Inflammatory Biomarkers and Negative Symptoms Subtypes in Individuals at Ultra-High Risk for Psychosis.

Journal: Early intervention in psychiatry

Published: January 04, 2025

The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures.

The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures.

Journal: Schizophrenia (Heidelberg, Germany)

Published: October 29, 2024

Psychosis Risk: Time to Look Empirically at a First-step Economical-pragmatic Way to Examine Anomalous Self-experience. Exploring the SQuEASE-11.

Psychosis Risk: Time to Look Empirically at a First-step Economical-pragmatic Way to Examine Anomalous Self-experience. Exploring the SQuEASE-11.

Journal: Schizophrenia bulletin

Published: September 06, 2024

Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership® Schizophrenia Program.

Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership® Schizophrenia Program.

Journal: Schizophrenia (Heidelberg, Germany)

Published: September 04, 2024

Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.

Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.

Journal: Schizophrenia (Heidelberg, Germany)

Published: September 04, 2024

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.

Journal: Schizophrenia (Heidelberg, Germany)

Published: August 28, 2024

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

Journal: Schizophrenia bulletin

Published: March 07, 2024

Erythrocyte membrane fatty acid concentrations and myelin integrity in young people at ultra-high risk of psychosis.

Erythrocyte membrane fatty acid concentrations and myelin integrity in young people at ultra-high risk of psychosis.

Journal: Psychiatry research

Published: November 29, 2023

A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial.

A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial.

Journal: JAMA psychiatry

Published: June 28, 2023

Showing 1-12 of 16

Last Updated: 09/26/2026